Shinji Higa
YOU?
Author Swipe
View article: Single-cell analysis reveals immune cell abnormalities underlying the clinical heterogeneity of patients with systemic sclerosis
Single-cell analysis reveals immune cell abnormalities underlying the clinical heterogeneity of patients with systemic sclerosis Open
The autoimmune disease systemic sclerosis (SSc) presents with multiple organ manifestations that often complicate management strategies. To explore variations in immune cell subsets and their link to clinical heterogeneity, here we perform…
View article: Spontaneous resolution of inflammatory myopathy involving the masseter muscle following COVID-19 mRNA vaccination
Spontaneous resolution of inflammatory myopathy involving the masseter muscle following COVID-19 mRNA vaccination Open
According to previous reports, most cases of inflammatory myopathy following messenger RNA (mRNA) vaccination can be classified as idiopathic inflammatory myopathy, particularly dermatomyositis, owing to their similar clinical features and…
View article: Influence of concomitant methotrexate use on the clinical effectiveness, retention, and safety of abatacept in biologic-naïve patients with rheumatoid arthritis:<i>Post-hoc</i>subgroup analysis of the ORIGAMI study
Influence of concomitant methotrexate use on the clinical effectiveness, retention, and safety of abatacept in biologic-naïve patients with rheumatoid arthritis:<i>Post-hoc</i>subgroup analysis of the ORIGAMI study Open
Objectives We performed post-hoc analyses of the ORIGAMI study to investigate whether concomitant methotrexate (MTX) influences the clinical outcomes of abatacept in biologic-naïve patients with rheumatoid arthritis. Methods Enrolled patie…
View article: Rapid attenuation of anti–<scp>SARS</scp>–<scp>CoV</scp>‐2 antibodies in patients with musculoskeletal diseases in whom intensive immunosuppressive therapies were reinitiated after <scp>COVID</scp>‐19: comment on the article by Curtis et al
Rapid attenuation of anti–<span>SARS</span>–<span>CoV</span>‐2 antibodies in patients with musculoskeletal diseases in whom intensive immunosuppressive therapies were reinitiated after <span>COVID</span>‐19: comment on the article by Curtis et al Open
We read with great interest the recently published, updated guidance from the American College of Rheumatology on COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases (RMDs) (1). Because the expected response to vac…
View article: Metagenome-wide association study of gut microbiome revealed novel aetiology of rheumatoid arthritis in the Japanese population
Metagenome-wide association study of gut microbiome revealed novel aetiology of rheumatoid arthritis in the Japanese population Open
Our shotgun sequencing-based MWAS highlights a novel link among the gut microbiome, host genome and pathology of RA, which contributes to our understanding of the microbiome's role in RA aetiology.
View article: IL-6 inhibitor for the treatment of rheumatoid arthritis: A comprehensive review
IL-6 inhibitor for the treatment of rheumatoid arthritis: A comprehensive review Open
Tocilizumab (TCZ) is an interleukin-6 (IL-6) inhibitor used for the treatment of rheumatoid arthritis (RA). It was developed in 2008, and its effectiveness is supported by evidence from all over the world based on its first decade of use. …